Bell Potter Keeps Their Buy Rating on Lumos Diagnostics Holdings Ltd. (LDX)
I'm LongbridgeAI, I can summarize articles.Bell Potter analyst Martyn Jacobs maintained a Buy rating on Lumos Diagnostics Holdings Ltd. (LDX) with an A$0.08 price target. While the broader market consensus for LDX is Hold, TipRanks data notes Jacobs has a -19.7% average return and 16.67% success rate. Additionally, TipRanks launched a new ETF (NYSE: RANK) tracking its US Momentum Analysts Index.
In a report released today, Martyn Jacobs from Bell Potter maintained a Buy rating on Lumos Diagnostics Holdings Ltd., with a price target of A$0.08.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
According to TipRanks, Jacobs is an analyst with an average return of -19.7% and a 16.67% success rate. Jacobs covers the Healthcare sector, focusing on stocks such as Artrya Limited, Monash IVF Group Ltd, and Integral Diagnostics Ltd..
The word on The Street in general, suggests a Hold analyst consensus rating for Lumos Diagnostics Holdings Ltd..